Earnings Growth of 0.9% Over 3 Years Hasn't Been Enough to Translate Into Positive Returns for Edwards Lifesciences (NYSE:EW) Shareholders
Earnings Growth of 0.9% Over 3 Years Hasn't Been Enough to Translate Into Positive Returns for Edwards Lifesciences (NYSE:EW) Shareholders
As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term Edwards Lifesciences Corporation (NYSE:EW) shareholders have had that experience, with the share price dropping 45% in three years, versus a market return of about 11%. The more recent news is of little comfort, with the share price down 22% in a year. Even worse, it's down 34% in about a month, which isn't fun at all. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.
作为投资者,值得努力确保您的整体投资组合能够超过市场平均水平。但是,选股的风险在于您很可能会购买表现不佳的公司。我们很遗憾地报告,长期持有爱德华生命科学公司(纽交所:EW)的股东们已经经历了这种经历,股价在三年内下跌了45%,而市场回报率约为11%。最近的消息更糟糕,股价在一年内下跌了22%。更糟糕的是,它在大约一个月内下跌了34%,这一点都不好玩。这可能与最近的财务业绩有关-您可以通过阅读我们的公司报告来了解最新的数据。
Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.
考虑到过去一周对股东来说是艰难的,让我们调查一下基本面并看看我们能学到什么。
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
为了概述本杰明·格雷厄姆(Benjamin Graham)的话:短期内,市场是一台投票机,但长期来看,它是一台衡重机。思考一家公司的市场感知如何转变的一种不完美但简单的方法是将每股收益(EPS)变化与股价变动进行比较。
During the unfortunate three years of share price decline, Edwards Lifesciences actually saw its earnings per share (EPS) improve by 2.9% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Alternatively, growth expectations may have been unreasonable in the past.
在不幸的三年股价下跌期间,爱德华生命科学实际上看到其每股收益(EPS)每年提高2.9%。考虑到股价的反应,人们可能会怀疑EPS并不是该时期业绩表现的良好指标(可能由于一次性损失或收益),或者过去的增长预期可能是不合理的。
After considering the numbers, we'd posit that the the market had higher expectations of EPS growth, three years back. But it's possible a look at other metrics will be enlightening.
经过综合数值分析后,我们断言市场在三年前对EPS的增长预期较高。但通过查看其他指标,可能能够找到收益。
We note that, in three years, revenue has actually grown at a 6.2% annual rate, so that doesn't seem to be a reason to sell shares. This analysis is just perfunctory, but it might be worth researching Edwards Lifesciences more closely, as sometimes stocks fall unfairly. This could present an opportunity.
我们注意到,在三年内,营业收入实际上已以6.2%的年均增长率增长,因此似乎没有卖出股票的理由。尽管这种分析只是敷衍了事,但深入研究爱德华生命科学可能是值得的,因为有时股票会不公正地下跌,这可能会带来机会。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
你可以在下面的图片中看到收入和营业收入随时间的变化情况(单击图表可查看精确值)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240809/0-7ace2fbcb9253880384fbecb1a0b6584-0-aae53da29e87197451386d8b38c908db.png/big)
Edwards Lifesciences is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates.
爱德华生命科学是一家知名股票,有许多分析师进行了覆盖,这表明未来增长有一定的可见度。鉴于我们拥有相当数量的分析师预测,检查描绘一致预期的免费图表可能非常值得。
A Different Perspective
不同的观点
Investors in Edwards Lifesciences had a tough year, with a total loss of 22%, against a market gain of about 16%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 3% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.
爱德华生命科学的投资者经历了困难的一年,总亏损达22%,而市场获得了约16%的收益。即使是好股票的股价有时也会下跌,但我们希望在产业基本指标改善之前不太感兴趣。不幸的是,去年的表现结束了糟糕的路程,股东在五年内面临年均3%的总亏损。总的来说,长期股价疲软可能是一个不好的迹象,尽管持反对意见的投资者可能希望研究股票,希望实现扭转局面。大多数投资者会花时间检查内部交易的数据。您可以点击此处查看内部人员是否一直在买卖。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
当然,您可能在其他地方找到一家出色的企业进行投资。因此,请查看我们预计将实现盈利增长的公司的免费列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。